Temporal Genomic Analysis of Homogeneous Tumor Models Reveals Key Regulators of Immune Evasion in Melanoma
In this study, we find that Mif expression is associated with tumor growth and aggressiveness, specifically in tumors with low heterogeneity. These findings could facilitate the development of new strategies to treat patients with homogeneous, high MIF-expressing tumors that are unresponsive to immune checkpoint therapy.
Authors
- Alejandro A. Schäffer (ORCID: https://orcid.org/0000-0002-2147-8033)
- Nofar Gumpert (ORCID: https://orcid.org/0009-0004-5589-6008)
- Roni Oren (ORCID: https://orcid.org/0000-0003-1228-412X)
- Ofra Golani (ORCID: https://orcid.org/0000-0002-9793-236X)
- Rony Dahan (ORCID: https://orcid.org/0000-0002-8420-7601)
- Liat Fellus-Alyagor (ORCID: https://orcid.org/0009-0001-9621-8068)
- Tomer‐Meir Salame (ORCID: https://orcid.org/0000-0003-4260-8738)
- Julia M. Martínez Gómez (ORCID: https://orcid.org/0000-0002-5684-3707)
- Winnie Yao (ORCID: https://orcid.org/0000-0003-1159-5153)
- Federica Sella (ORCID: https://orcid.org/0000-0002-0805-0905)
- Kamir J. Hiam-Galvez (ORCID: https://orcid.org/0000-0002-1956-0257)
- Osnat Bartok
- Mitchell Paul Levesque (ORCID: https://orcid.org/0000-0001-5902-9420)
- Ori Brenner (ORCID: https://orcid.org/0000-0001-8221-7278)
- Peter P. Du (ORCID: https://orcid.org/0000-0003-2652-0541)
- Mirie Zerbib (ORCID: https://orcid.org/0009-0008-4074-1344)
- Yajie Yin (ORCID: https://orcid.org/0000-0002-2220-005X)
- Nadav Ketrarou (ORCID: https://orcid.org/0009-0006-7608-9584)
- Yardena Samuels (ORCID: https://orcid.org/0000-0002-3349-7266)
- Kuoyuan Cheng (ORCID: https://orcid.org/0000-0001-8118-5243)
- Shifra Ben‐Dor (ORCID: https://orcid.org/0000-0001-9604-1939)
- Ronen Levy (ORCID: https://orcid.org/0000-0002-9574-2132)
- Ansuman T. Satpathy (ORCID: https://orcid.org/0000-0002-5167-537X)
- Colin J. Raposo (ORCID: https://orcid.org/0000-0002-5230-7931)
- Marie J. Zemanek (ORCID: https://orcid.org/0009-0000-5401-9100)
- Ilya Savchenko (ORCID: https://orcid.org/0009-0002-1709-1079)
- Eytan Ruppin (ORCID: https://orcid.org/0000-0002-7862-3940)
- Michèle Welti (ORCID: https://orcid.org/0000-0001-7759-7288)
- Inna Goliand (ORCID: https://orcid.org/0000-0002-1595-5366)
- Irit Orr (ORCID: https://orcid.org/0009-0006-0111-0481)
- Sapir Cohen Shvefel
- Elizabeta Yakubovich (ORCID: https://orcid.org/0009-0003-3030-6385)
- Dean Ranmar (ORCID: https://orcid.org/0009-0009-1992-6819)
- Yingying Cao (ORCID: https://orcid.org/0009-0002-0604-5894)
- Lipika R. Pal (ORCID: https://orcid.org/0000-0002-3390-110X)
- Ella Herzog (ORCID: https://orcid.org/0009-0006-1670-0257)
- Chen Weller
- Joy A. Pai (ORCID: https://orcid.org/0009-0000-3529-6671)
Institutions
- Merck & Co., Inc., Rahway, NJ, USA (United States) (US)
- National Institutes of Health (US)
- Gladstone Institutes (US)
- University of California, San Francisco (US)
- University of Zurich (CH)
- Chinese Mathematical Society (CN)
- University Hospital of Zurich (CH)
- Parker Institute for Cancer Immunotherapy (US)
- National Cancer Institute (US)
- Weizmann Institute of Science (IL)
- Stanford University (US)
Publication Details
- Journal
- Cancer Discovery
- Published
- 2024-11-20
- DOI
- https://doi.org/10.1158/2159-8290.cd-23-1422
- Citations
- 10
- Primary Topic
- Cancer Immunotherapy and Biomarkers
- Type
- article
- Field-Weighted Citation Impact
- 2.83